Acknowledgements

• Peter Willett

  • University of Sheffield, UK

• John Bradshaw

  • GlaxoWellcome, UK

• GlaxoWellcome for funding

• The Daylight Krewe for software and help

Previous slide

Back to first slide

View graphic version